Amgen Inc. (NASDAQ:AMGN) Given Average Rating of “Hold” by Brokerages

Amgen Inc. (NASDAQ:AMGN) has been given a consensus rating of “Hold” by the thirty ratings firms that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, fifteen have assigned a hold recommendation, eleven have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $356.6154.

A number of brokerages recently weighed in on AMGN. Erste Group Bank reaffirmed a “hold” rating on shares of Amgen in a research note on Tuesday, May 5th. Weiss Ratings cut Amgen from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday. Morgan Stanley decreased their target price on Amgen from $340.00 to $333.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 8th. UBS Group lifted their price target on Amgen from $400.00 to $420.00 and gave the stock a “buy” rating in a research note on Monday. Finally, The Goldman Sachs Group set a $389.00 price target on Amgen in a research report on Friday, June 5th.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.85% of the stock is owned by insiders.

Institutional Trading of Amgen

A number of hedge funds have recently bought and sold shares of AMGN. Anfield Capital Management LLC lifted its position in Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares in the last quarter. Dogwood Wealth Management LLC increased its stake in shares of Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after acquiring an additional 55 shares during the last quarter. Board of the Pension Protection Fund purchased a new position in shares of Amgen during the 4th quarter worth $26,000. Tower View Wealth Management LLC raised its holdings in shares of Amgen by 331.6% during the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after acquiring an additional 63 shares during the period. Finally, Manning & Napier Advisors LLC boosted its position in shares of Amgen by 49.2% during the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 32 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $371.58 on Friday. The firm has a market cap of $200.55 billion, a PE ratio of 25.86, a PEG ratio of 3.63 and a beta of 0.41. The firm has a fifty day moving average of $347.00 and a 200 day moving average of $350.27. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. Amgen has a one year low of $269.77 and a one year high of $391.29.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same period last year, the firm posted $4.90 earnings per share. The company’s revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, research analysts predict that Amgen will post 22.31 EPS for the current fiscal year.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.